• Bridging therapy often required. Long wait times between the initial collection of the patient's T cells and the return of the manufactured cells back to the patient may require bridging therapy, an additional line of therapy. • Manufacturing constraints. At present, there are a limited number of CAR-T cell centers and there are often insufficient manufacturing slots available to meet patient demand for autologous therapies. In addition, autologous cell manufacturing is complex and lengthy, and there can ...

Exhibit 99.1 Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update -- 30 patient dosed in CB-010 ANTLER Phase 1 trial dose expansion; initial dose expansion data and RP2D to be disclosed in Q2 2024 -- th -- 1 patient dosed in CB-012 AMpLify Phase 1 trial for patients with r/r AML -- st -- $372.4 million in cash, cash equivalents, and marketable securities expected to fund the current operating plan into Q1 2026 -- BERKELEY, Calif., March 11, 2024 (GLOBE ...

BERKELEY, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following investor conferences: Citi's 2024 Virtual Oncology Leadership SummitFebruary 21, 2024, fireside chat at 12:00 pm EST Leerink Global Biopharma ConferenceMarch 12, 2024, fireside chat at 1:40 pm EDT Barclays Global Healthcare ConferenceMarch 13, 2024 H.C. Wainwright 2nd Annual Cell Th ...

Cash Used in Operating Activities 32 During the nine months ended September 30, 2023, cash used in investing activities was $36.7 million, and during the nine months ended September 30, 2022, cash used in investing activities was $94.4 million. During the nine months ended September 30, 2023, and 2022, cash provided by financing activities was $154.3 million and $2.0 million, respectively. Our critical accounting policies are disclosed in our audited consolidated financial statements for the year ended Dece ...

A single dose of CB-010 resulted in profound tumor regression of metastatic CD19+ tumor xenografts and led to a significantly longer antitumor response and survival vs. conventional CD19-specific allogeneic CAR-T cells (expressing PD-1) | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-----------------------------|-------|-------|-------|-------|-------|---------------------|-------|-------| | PBS (negative control) | | | | | | 100 | | | | CD19 CAR-T (PD-1 positive) | | | | | | Percent survival 50 | ...

FORM 10-Q Table of Contents The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Liquidity Licensees that represent 10% or more of our revenue and accounts receivable and contract assets were as follows: Table of Contents Page PART I. FINANCIAL INFORMATION 1 Item 1. Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations and Comprehensive Loss 2 Condensed Consolidated Statements of Stock ...

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities. events versus 1 CRISPR Fewer off-target st generation Time 11 Corporate Presentation | May 2023 ©2023 Caribou Biosciences, Inc. Healthy donor leukapheresis-derived T cells ©2023 Caribou Biosciences, Inc. All statements in this presentation, other than statements of historical facts, are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. These for ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ______________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40631 ______________________________________ Caribou Biosciences, Inc. ( ...

Experienced management team Corporate presentation Transformative genome-edited therapies for patients In light of the foregoing, you are urged not to rely on any forward-looking statement or third-party data in reaching any conclusion or making any investment decision about any securities of the Company. The forward-looking statements in this presentation are made only as of the date hereof. Except to the extent required by law, the Company assumes no obligation and does not intend to update any of these f ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 __________________________________ For the fiscal year ended December 31, 2022 For the transition period from to Delaware 45-3728228 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes o No x Indicate by c ...